TripleBar Bio, Inc.
Emeryville, US · Founded 2019 · Delaware corporation · 4 known investors
Triplebar builds an AI platform for Genomic Design Automation (GDA), using microfluidics to generate large-scale biological datasets with matched genotype and phenotype at lower cost and faster than liquid handling robotics. It applies machine learning to biological data to support biotechnology research and product engineering.
AI & Machine LearningBiotechDeep Tech
Founders & leadership
TripleBar Bio, Inc. was founded in 2019 by Jeremy Agresti.
Board
RW
Rose WardleBoard director
DF
David Friedbergin𝕏Board directorFounder & CEO of The Production Board; CEO of Ohalo Genetics; All-In co-host
Investors · 4
Reported raises · per SEC filings
Form D private placements$19.8M disclosed across 1 round · 2023
▶$19.8MraisedOct 2023 · 9 investors · BiotechnologyRule 506(b)
▶$19.8MraisedOct 2023 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rose WardleDirector
- Howard LevinDirector
- David FriedbergDirector
- Maria ChoExecutive Officer, Director
- Offering amount
- $20.5M
- Amount sold
- $19.8M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap3Bar Biologics7 shared keywords
Agfundernews6 shared keywordsAgFunderNews is a news publication covering agrifood technology, including alternative protein, agtech, and foodtech companies and industry developments.
IQ Bar4 shared keywordsIQBAR sells plant protein bars, hydration mixes (IQMIX), and instant coffees (IQJOE) formulated with nutrients such as magnesium and adaptogens. The direct-to-consumer products are marketed as vegan, low sugar, keto/paleo, non-GMO, seed oil free, and gluten free.
32 Biosciences Website4 shared keywords32 Biosciences develops gut mucosal-immune science to prevent and treat gastrointestinal diseases, offering a GI discovery platform that measures metabolomic signatures of the gut mucosal-immune system and a therapeutic platform based on a Mucosal Immune Modulator (MIM) that restores and protects the gastrointestinal mucosal-immune barrier. Its lead therapeutic asset is CS-0003.
Gritdaily3 shared keywordsGrit Daily is an online news publication covering startups, entrepreneurship, technology, and business trends through articles and founder profiles. It functions as a digital media outlet reporting on topics such as AI, supply chains, and consumer brands.
ClickBio, Inc.3 shared keywordsClickBio designs and manufactures laboratory automation tools and consumables, such as its Smarter Reagent Fill Station, an automation-ready on-deck reservoir with USB-B connectivity and serial command control for continuous media replenishment. The products target life science labs for applications including Next Generation Sequencing (NGS) and cell culture, built by a team of mechanical engineers and scientists.
Companies competing with TripleBar Bio, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does TripleBar Bio, Inc. do?
- Triplebar builds an AI platform for Genomic Design Automation (GDA), using microfluidics to generate large-scale biological datasets with matched genotype and phenotype at lower cost and faster than liquid handling robotics. It applies machine learning to biological data to support biotechnology research and product engineering.
- Who founded TripleBar Bio, Inc.?
- TripleBar Bio, Inc. was founded by Jeremy Agresti in 2019.
- Who are TripleBar Bio, Inc.'s investors?
- TripleBar Bio, Inc.'s investors include iSelect Fund, Stray Dog Capital, Synthesis Capital, TPB.
- How much funding has TripleBar Bio, Inc. raised?
- TripleBar Bio, Inc. has disclosed $19.8M raised across 1 round.
- Where is TripleBar Bio, Inc. headquartered?
- TripleBar Bio, Inc. is headquartered in Emeryville, US.